Enfuvirtide (Fuzeon)

Published March 17, 2003; Updated September 21, 2007
Susa Coffey, MD
http://hivinsite.ucsf.edu/InSite?page=ar-04-01
Selected Reference
9. Greenberg ML, Melby T, Sista P, DeMasi R, Cammack N, Salgo M, Whitcomb J, Petropoulos C, Matthews TJ. Baseline and on-treatment susceptibility to Enfuvirtide seen in TORO 1 and TORO 2 to 24 weeks. 10th Conference on Retroviruses and Opportunistic Infections. February 10-14, 2003, Boston. Abstract 141.